What are the exercise prices and share counts of the new ARTL warrants?

One warrant covers 38,346 shares at $6.24 ; another covers 70,376 shares at $3.40 .

Artelo Biosciences insider files Form 4 with two new warrants

Q: When do the ARTL warrants expire?

Both warrants have an expiration date of October 28, 2030 .

Q: What are the key terms of the October Note for ARTL?

The filing lists a principal amount of $110,843 , exercisable from October 28, 2025 and expiring on April 28, 2026 , and states it is convertible into common stock.

Q: What was the earliest transaction date reported?

The earliest transaction date disclosed is October 28, 2025 .

Q: What is the insider’s relationship to ARTL?

The reporting person is a Director of Artelo Biosciences, Inc.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Artelo Biosciences (ARTL): Director insider transaction reported. On October 28, 2025, a portion of a convertible note issued on May 1, 2025 was automatically converted into a warrant to buy 38,346 shares of common stock at an exercise price of $6.24, expiring October 28, 2030.

On the same date, under a Subscription Agreement, the remaining portion of the May note held by the reporting person was converted and reinvested into (i) a new convertible note (the “October Note”) and (ii) a warrant to buy 70,376 shares at $3.40, expiring October 28, 2030. The filing indicates a principal amount of $110,843 for the October Note, which is convertible into common stock and lists dates of exercisability beginning October 28, 2025 and expiration on April 28, 2026.

Insider Trade Summary

108,722 shares exercised/converted

Mixed 4 txns

Insider MATSUI CONNIE

Role Director

Type	Security	Shares	Price	Value
Conversion	Convertible Promissory Note	0	$140,000.00	--
Conversion	Warrant (right to buy)	38,346	$0.00	--
Conversion	Warrant (right to buy)	70,376	$0.00	--
Conversion	Convertible Promissory Note	0	$110,843.00	--

Holdings After Transaction: Convertible Promissory Note — 0 shares (Direct); Warrant (right to buy) — 38,346 shares (Direct)

Footnotes (1)

Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Form 4 Insider Transactions: What Each Field Means →

10/30/2025 - 09:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATSUI CONNIE

(Last)

(First)

(Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Convertible Promissory Note	⁽¹⁾⁽²⁾	10/28/2025		C⁽²⁾⁽¹⁾			$140,000	05/01/2025	10/28/2025	Common Stock	⁽²⁾⁽¹⁾	$140,000	$0.00	D
Warrant (right to buy)	$6.24	10/28/2025		C⁽²⁾⁽¹⁾		38,346		10/28/2025	10/28/2030	Common Stock	38,346	⁽¹⁾⁽²⁾	38,346	D
Warrant (right to buy)	$3.4	10/28/2025		C⁽²⁾⁽¹⁾		70,376		10/28/2025	10/28/2030	Common Stock	70,376	⁽²⁾⁽¹⁾	70,376	D
Convertible Promissory Note	$3.4	10/28/2025		C⁽¹⁾⁽²⁾		$110,843		10/28/2025	04/28/2026	Common Stock	⁽¹⁾⁽²⁾	$110,843	$110,843	D

Explanation of Responses:

1. Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

2. On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ARTL’s director report on Form 4?

A portion of a May 1, 2025 convertible note converted into a $6.24 warrant for 38,346 shares, and the remainder was reinvested into an October convertible note and a $3.40 warrant for 70,376 shares.

When do the ARTL warrants expire?

Both warrants have an expiration date of October 28, 2030.

What are the key terms of the October Note for ARTL?

The filing lists a principal amount of $110,843, exercisable from October 28, 2025 and expiring on April 28, 2026, and states it is convertible into common stock.

What was the earliest transaction date reported?

The earliest transaction date disclosed is October 28, 2025.

What is the insider’s relationship to ARTL?

The reporting person is a Director of Artelo Biosciences, Inc.